Sarah Meadows
Impact in
Papers in
- Genetics 17
- Chronic Lymphocytic Leukemia Research 17
-
- PI3K/AKT/mTOR signaling in cancer 8
- Co-authors
- Brian J. Lannutti (13 shared papers)Neill A. Giese (5 shared papers)Adam Kashishian (11 shared papers)Lily Yeh Jan (2 shared papers)Linda Sharp (2 shared papers)Yuh Nung Jan (2 shared papers)Langdon L. Miller (3 shared papers)Sige Zou (1 shared paper)
- Journals
- Blood (14 papers)Cancer Research (2 papers)Genetics (1 paper)Oncotarget (1 paper)PLoS ONE (1 paper)
- Partner nations
- United StatesGermany
In The Last Decade
Sarah Meadows
23 papers receiving 1.7k citations
Sarah Meadows's Hit Papers
Peers
Comparison fields: 5 of 83
- Genetics 867
- Aging 102
- Pathology and Forensic Medicine 552
- Hematology 248
- Immunology 377
Countries citing papers authored by Sarah Meadows
This map shows the geographic impact of Sarah Meadows's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Meadows with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Meadows more than expected).
Fields of papers citing papers by Sarah Meadows
This network shows the impact of papers produced by Sarah Meadows. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Meadows. The network helps show where Sarah Meadows may publish in the future.
Co-authors
The 25 scholars most cited alongside Sarah Meadows, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Hit paper breakdown → | 2010 | 592 |
| 2 | The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Hit paper breakdown → | 2011 | 445 |
| 3 | 2000 | 247 | |
| 4 | 2011 | 116 | |
| 5 | 2000 | 89 | |
| 6 | 2014 | 55 | |
| 7 | 2017 | 38 | |
| 8 | 2007 | 25 | |
| 9 | 2015 | 22 | |
| 10 | 2010 | 13 | |
| 11 | 2000 | 8 | |
| 12 | 2011 | 7 | |
| 13 | 2010 | 7 | |
| 14 | 2009 | 6 | |
| 15 | 2015 | 4 | |
| 16 | 2013 | 4 | |
| 17 | 2015 | 4 | |
| 18 | 2015 | 4 | |
| 19 | 2008 | 3 | |
| 20 | 2012 | 2 |
About Sarah Meadows
Sarah Meadows is a scholar working on Genetics, Molecular Biology, Pathology and Forensic Medicine, Oncology and Immunology, having authored 23 papers that have together received 1.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer-related Molecular Pathways (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Acute Lymphoblastic Leukemia research (2 papers), Immunodeficiency and Autoimmune Disorders (2 papers) and Advanced Breast Cancer Therapies (2 papers). The work is most often cited by research in Genetics (867 citations), Aging (102 citations), Pathology and Forensic Medicine (552 citations), Hematology (248 citations) and Immunology (377 citations). Sarah Meadows has collaborated with scholars based in United States and Germany. Frequent co-authors include Brian J. Lannutti, Neill A. Giese, Adam Kashishian, Lily Yeh Jan, Linda Sharp, Yuh Nung Jan, Langdon L. Miller, Sige Zou, Brian Druker and Marc Loriaux. Their work appears in journals such as Blood, Cancer Research, Genetics, Oncotarget and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.